Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...4748495051525354555657...858859»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity. (Pubmed Central) -  Jul 22, 2024   
    The pharmaco-economic evidence generated from this study has significant implications not only for guiding the drug pricing of the upcoming sotorasib but also for determining the reimbursement ratio for its potential inclusion in the National Reimbursement Drugs List in the future. Our work uncovers a novel function of DYNLL1 in orchestrating cell cycle to promote HCC development and suggests a potential synergy of CDK4/6 inhibitor and sorafenib for the treatment of HCC patients, especially those with increased DYNLL1.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Talzenna (talazoparib) / Pfizer
    Journal, BRCA Biomarker, PARP Biomarker:  FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer. (Pubmed Central) -  Jul 22, 2024   
    Additionally, the CDK4/6 inhibitor palbociclib enhanced the sensitivity of breast cancer cells to talazoparib through FANCI inhibition. These findings highlight the potential of targeting FANCI to enhance the efficacy of PARP inhibitors in treating breast cancer.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Research progress on perioperative management of tooth extraction in denosumab-treated patients (Pubmed Central) -  Jul 22, 2024   
    However, the perioperative management strategies for DRONJ differ from those for bisphosphonate-related osteonecrosis of the jaw. This article summarizes the perioperative management strategies for high-risk DRONJ patients from aspects such as oral hygiene care, antibiotic use, drug discontinuation during the perioperative period, and surgical strategy selection, aiming to provide guidance for oral surgeons in managing tooth extraction in denosumab-treated patients.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Denosumab: A Useful Addition to the Armamentarium for the Management of Male Osteoporosis. (Pubmed Central) -  Jul 22, 2024   
    Multiple studies suggest that denosumab is both effective and safe, exhibiting higher adherence rates and greater patient satisfaction. In this narrative review, we highlighted the effects of denosumab in men with osteoporosis, subsequent changes in bone mineral density, and bone turnover markers outlining the literature and guideline support.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Retrospective data, Review, Journal:  Monoclonal antibodies in patients with osteoporosis and renal insufficiency: An updated systematic review and meta-analysis. (Pubmed Central) -  Jul 22, 2024   
    There was no statistically significant difference in the change of estimated glomerular filtration rate and in the incidence of hypocalcemia and serious adverse events between groups. There were reductions in both vertebral and nonvertebral fracture risks, alongside improvements in BMD among patients with renal insufficiency treated with MAb.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal:  Clinical efficacy of tezepelumab in pre-selected non-type 2 asthma patients. (Pubmed Central) -  Jul 22, 2024   
    There was no difference in treatment use between urban and rural areas after adjusting for risk factors, although the specific treatment used, and adherence, differed. No abstract available
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    FDA event, Journal:  AI-based 3D-QSAR model of FDA-approved repurposed drugs for inhibiting sclerostin. (Pubmed Central) -  Jul 20, 2024   
    The Wnt pathway antagonist sclerostin and additional anti-sclerostin antibodies were discovered as a result of the development of the monoclonal antibody romosozumab...The test set demonstrated the model's robustness. This research may aid in the development of more effective sclerostin inhibitors that are synthesised using FDA-approved medications.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Journal:  Is JAK effective in treating recurrent SAPHO syndrome? TwHF might be a good choice. (Pubmed Central) -  Jul 19, 2024   
    In this study, TwHF was successful in treating a patient with refractory SAPHO syndrome who was refractory to multiple Western medications without significant adverse effects or toxicities, but further follow-up is needed to determine long-term efficacy. More case reports as well as clinical trials are still needed to confirm whether TwHF can effectively treat refractory SAPHO syndrome.
  • ||||||||||  Journal, Adverse events, Real-world evidence, Real-world:  Safety of TNF-? inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database. (Pubmed Central) -  Jul 19, 2024   
    The analysis indicates that infliximab is associated with 60 unique positive ADEs, including Hodgkin's disease, metastatic neoplasm, and non-Hodgkin's lymphoma; therefore, these patients should use infliximab with greater caution. Similarly, certolizumab should be used with increased caution in pregnant and postpartum women.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Retrospective data, Review, Journal:  Utility of a bone health clinic in bridging the osteoporosis care gap: Prescribing habit review at an academic institution. (Pubmed Central) -  Jul 18, 2024   
    The efficacy and safety of tezepelumab in patients with symptomatic and histologically active EoE are being assessed in the ongoing CROSSING study. Establishing a bone health clinic dedicated to osteoporosis management leads to significantly higher prescription rates per provider, increased utilization of anabolic therapies compared to other specialties, and more male patients being treated-an often-neglected population in osteoporosis.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor-induced arrest. (Pubmed Central) -  Jul 18, 2024   
    Here, by expressing the APC/C inhibitor, EMI1, we show that APC/C activity is essential to prevent S phase entry in cells arrested by pharmacological cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition (Palbociclib)...As a result, DNA synthesis and cell proliferation are profoundly impaired. Our findings predict that cancers with elevated EMI1 expression will tend to escape CDK4/6 inhibition into a premature, underlicensed S phase and suffer enhanced genome instability.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Giant cell tumor of femur with single pulmonary metastasis - yet another curative oligometastasis. (Pubmed Central) -  Jul 18, 2024   
    We report a case of GCT with solitary pulmonary metastasis who had significant clinical benefit and disease control with sequential application of surgical resection of pulmonary metastasis, local external beam radiation therapy (EBRT), and systemic Denosumab. We wish to highlight that even in metastatic GCT, there is significant clinical benefit in aggressive treatment.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Tafinlar (dabrafenib) / Novartis, BeiGene
    Journal:  The Raf kinase inhibitors Dabrafenib and Regorafenib impair Zika virus replication via distinct mechanisms. (Pubmed Central) -  Jul 18, 2024   
    Because these inhibitors affect distinct post-entry steps of ZIKV infection, their therapeutic potential may be amplified by combination therapy and likely does not require prophylactic administration. This study provides further insight into ZIKV-host interactions and has implications for the development of novel antivirals against ZIKV and possibly other flaviviruses.
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin
    Clinical data, Retrospective data, Journal:  Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes. (Pubmed Central) -  Jul 18, 2024   
    Romiplostim is a well-tolerated and promising treatment for primary ITP in dogs, suggesting its potential as a valuable therapeutic option for dogs with thrombocytopenia caused by various underlying conditions. These findings emphasize the need for further research to optimize romiplostim dosing and understand its role in treating secondary thrombocytopenia and pancytopenia of unknown etiology.
  • ||||||||||  Retrospective data, Review, Journal:  A Risk-Difference Meta-Analysis for the Prophylactic Treatments of Chronic Migraine. (Pubmed Central) -  Jul 18, 2024   
    Four mAbs, namely, erenumab, fremanezumab, galcanezumab, and eptinezumab, have been marketed, although head-to-head trials with standard anti-migraine treatments are absent...The two studies of topiramate showed contradictory results, the one significant while the other not, with NNTs 2 and 22, respectively. All four anti-CGRP mAbs showed an invariably high efficacy among their studies, in terms of the ARD and its derivative measure of NNT, in contrast to oBTA, while in topiramate, the results are contradictory between the two studies.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Trial completion date, Trial primary completion date:  PRECISE: Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis (clinicaltrials.gov) -  Jul 18, 2024   
    P1,  N=30, Not yet recruiting, 
    All four anti-CGRP mAbs showed an invariably high efficacy among their studies, in terms of the ARD and its derivative measure of NNT, in contrast to oBTA, while in topiramate, the results are contradictory between the two studies. Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
  • ||||||||||  Prolia (denosumab) / Amgen
    Giant Cell tumour of bone a progressing danger (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_1975;    
    It usually develops near a joint at the end of the bone. Most occur in the long bones of the legs and arms.Giant cell tumors most often occur in young adults when skeletal bone growth is complete.The exact cause of giant cell tumors remains unknown.Symptoms may include joint pain, swelling, and limited movement.Diagnostic tests may include X-rays, biopsy, and bone scans.The goal for treatment of a giantcell tumor is to remove the tumor and prevent damage to the affected bone.Tumors that can't be removed surgically can often be controlled and sometimes destroyed with radiation therapy.Giant cell tumors can come back.
  • ||||||||||  ivabradine / Generic mfg.
    Comparison of non-selective HCN and selective HCN2 inhibitors in rat assays of peripheral nerve exci (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_1779;    
    Our results demonstrate a lack of improved analgesic efficacy or therapeutic index by selectively inhibiting HCN2 channels in rats. Non-selective HCN inhibition (using MSD-1) resulted in attenuation of ectopia in peripheral nerves and induces analgesia in rodents with nerve injury.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Trial completion, Trial completion date, Trial primary completion date:  FITTER: Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody (clinicaltrials.gov) -  Jul 18, 2024   
    P=N/A,  N=150, Completed, 
    Non-selective HCN inhibition (using MSD-1) resulted in attenuation of ectopia in peripheral nerves and induces analgesia in rodents with nerve injury. Recruiting --> Completed | Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Nov 2023
  • ||||||||||  Opdivo (nivolumab) / BMS, Repatha (evolocumab) / Amgen, Astellas, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  TOP2101: A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Na (clinicaltrials.gov) -  Jul 17, 2024   
    P2,  N=38, Recruiting, 
    Active, not recruiting --> Recruiting Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2023 --> Jun 2025